SCHEMBL3341387

SCHEMBL3341387

O=C(NNc1nc(-c2ccc3ccccc3c2)cs1)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.60
KDM4E B2RXH2 9/20 0.60
GAA P10253 9/20 0.60
MEN1 O00255 6/20 0.60
KMT2A Q03164 6/20 0.60
HTT P42858 5/20 0.60
ALDH1A1 P00352 5/20 0.60
TDP1 Q9NUW8 3/20 0.60
LMNA P02545 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
MAPK1 P28482 3/20 0.57
CSNK2A1 P68400 2/20 0.55
RAB9A P51151 3/20 0.55
NPC1 O15118 2/20 0.55
GSTO1 P78417 1/20 0.52
AR P10275 1/20 0.51
PTGES O14684 1/20 0.51
HPGD P15428 1/20 0.51
VCP P55072 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336646 0.82 KDM4E (0.76) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL3344076 0.80 MAPT (0.66) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL6248973 0.80 MAPT (0.67) MAPTKDM4EMEN1KMT2AMAPK1
SCHEMBL3341776 0.79 MAPT (0.89) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL3337831 0.78 MAPT (0.52) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL6252950 0.77 KDM4E (0.63) MAPTKDM4EMEN1KMT2ATDP1
SCHEMBL3337680 0.77 CA12 (0.62) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL3338690 0.76 RAB9A (0.55) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL3344724 0.76 KDM4E (1.00) MAPTKDM4EGAAMEN1KMT2A
SCHEMBL31265595 0.76 PARP1 (0.74) MAPTMEN1KMT2AHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US claimed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO claimed
US-8410152-B2 Thiazolhydrazides for treatment of neurodegenerative diseases MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E. V. (DE) 2013-04-02 US disclosed
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES TECHNISCHE UNIVERSITAT DARMSTADT (DE) 2010-06-17 US disclosed
WO-2008052804-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151064-A1 THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA MAPT 2/4885KDM4E 4489/4885GAA 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.